Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia

Leukemia Research

Volumn 35, Issue 8, 2011, Pages 1014-1019

  Maffioli, Margherita ^a   Camós, Mireia ^a   Gaya, Anna ^a   Hernández Boluda, Juan Carlos ^b   Álvarez Larrán, Alberto ^c   Domingo, Abel ^a   Granell, Miquel ^a   Guillem, Vicent ^b   Vallansot, Rolando ^a   Costa, Dolors ^d   Bellosillo, Beatriz ^c   Colomer, Dolors ^d   Cervantes, Francisco ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Chronic myeloid leukemia; Genetic polymorphisms; HOCT1; Imatinib; MDR1; Therapy

Indexed keywords

IMATINIB;

ADULT; AGED; ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GENE; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HOCT1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; ORGANIC CATION TRANSPORTER 1; P-GLYCOPROTEIN; PIPERAZINES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PYRIMIDINES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960284293     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.12.004     Document Type: Article

References (36)

1. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344(April (14)):1031-1037.
2. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(March (11)):994-1004.
3. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(December (23)):2408-2417.
4. de Lavallade H., Apperley J.F., Khorashad J.S., Milojkovic D., Reid A.G., Bua M., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26(July (20)):3358-3363.
5. Cervantes F., López-Garrido P., Montero M., Jonte F., Martínez J., Hernández-Boluda J., et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia. A study of the Spanish PETHEMA group. Haematologica 2010, 95(March (8)):1317-1324.
6. Hochhaus A., Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004, 18(June(3)):641-656. ix.
7. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003, 102(July (1)):276-283.
8. O'Hare T., Eide C.A., Deininger M.W.N. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110(October (7)):2242-2249.
9. Thomas J., Wang L., Clark R.E., Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104(December (12)):3739-3745.
10. White D.L., Saunders V.A., Dang P., Engler J., Venables A., Zrim S., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007, 110(December (12)):4064-4072.
11. White D.L., Dang P., Engler J., Frede A., Zrim S., Osborn M., et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010, 28(June (16)):2761-2767.
12. Bazeos A., Marin D., Reid A.G., Gerrard G., Milojkovic D., May P.C., et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 2010, 24(June (6)):1243-1245.
13. Kim D.H.D., Sriharsha L., Xu W., Kamel-Reid S., Liu X., Siminovitch K., et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin. Cancer Res. 2009, 15(July (14)):4750-4758.
14. Wang L., Giannoudis A., Lane S., Williamson P., Pirmohamed M., Clark R.E. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008, 83(February (2)):258-264.
15. White D.L., Saunders V.A., Dang P., Engler J., Hughes T.P. OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. Leukemia 2010, 24(November (11)):1962-1965.
16. Mahon F., Belloc F., Lagarde V., Chollet C., Moreau-Gaudry F., Reiffers J., et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101(March (6)):2368-2373.
17. Gurney H., Wong M., Balleine R.L., Rivory L.P., McLachlan A.J., Hoskins J.M., et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 2007, 82(July (1)):33-40.
18. Dulucq S., Bouchet S., Turcq B., Lippert E., Etienne G., Reiffers J., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008, 112(September (5)):2024-2027.
19. Gabert J., Beillard E., van der Velden V.H.J., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer Program. Leukemia 2003, 17(October (12)):2318-2357.
20. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108(July (1)):28-37.
21. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27(December (35)):6041-6051.
22. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99(May (9)):3472-3475.
23. Stephens M., Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003, 73(November (5)):1162-1169.
24. Solé X., Guinó E., Valls J., Iniesta R., Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006, 22(August (15)):1928-1929.
25. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002, 70(February (2)):425-434.
26. Wong M., Evans S., Rivory L.P., Hoskins J.M., Mann G.J., Farlow D., et al. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther 2005, 77(January (1)):33-42.
27. Larson R.A., Druker B.J., Guilhot F., O'Brien S.G., Riviere G.J., Krahnke T., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111(April (8)):4022-4028.
28. Zhang W.W., Cortes J.E., Yao H., Zhang L., Reddy N.G., Jabbour E., et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009, 27(August (22)):3642-3649.
29. Marin D., Bazeos A., Mahon F., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28(May (14)):2381-2388.
30. Crossman L.C., Druker B.J., Deininger M.W.N., Pirmohamed M., Wang L. Clark RE. hOCT 1 and resistance to imatinib. Blood 2005, 106(August (3)):1133-1134.
31. Shu Y., Leabman M.K., Feng B., Mangravite L.M., Huang C.C., Stryke D., et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A 2003, 100(May (10)):5902-5907.
32. Shu Y., Sheardown S.A., Brown C., Owen R.P., Zhang S., Castro R.A., et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007, 117(May (5)):1422-1431.
33. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., Sadée W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005, 15(October (10)):693-704.
34. Kimchi-Sarfaty C., Oh J.M., Kim I., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A silent polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315(January (5811)):525-528.
35. Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006, 12(December (24)):7374-7379.
36. Khorashad J.S., de Lavallade H., Apperley J.F., Milojkovic D., Reid A.G., Bua M., et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008, 26(October (29)):4806-4813.